NEW YORK (GenomeWeb) – Cellular Dynamics International and Nanion Technologies have entered into a comarketing agreement to offer CDI's human induced pluripotent stem cell-derived tissue cells with Nanion's ion channel drug discovery and screening platform.
Under the terms of the agreement, customers will receive Nanion's CardioExcyte 96 instrument in conjunction with a supply and participation agreement with CDI, a Madison, Wisconsin-based subsidiary of FujiFilm. Specifically, CDI will provide iPSC-derived differentiated cells, and Nanion will provide on-site training for CardioExcyte use. At the end of a year, customers can renew their contract or purchase the CardioExcyte 96 instrument at a discount.
The companies also said that they will continue to develop and expand applications offered under this program.
CardioExcyte 96 measures cellular electrical activity, movement, and morphology changes, and has applications in basic research, toxicity testing, and therapeutic development "across a suite of endpoints including, but not limited to cardiac function, cell attachment, spreading and proliferation, quantification of cell behavior in a confluent layer … and quality of cell-cell and cell-substrate adhesions," Nanion Technologies Founder and CEO Niels Fertig said in a statement. "CDI produces many cell types central to these endpoints and we are excited to launch this combined effort that bundles and increases access to these technologies."